Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2001-01-17
2004-07-06
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S183000, C435S212000, C435S219000, C435S424000, C435S094000, C435S094000
Reexamination Certificate
active
06759227
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
Caspases are cysteinyl aspartate-specific proteinases, many of which play a central role in apoptosis. This invention relates to the identification of a new murine caspase and its human homologue. The new molecules are most related to human/murine caspase-2 and human caspase-9 and possesses all the typical amino acid residues of the caspases involved in catalysis, including the QACRG box, and contains none, or only a very short prodomain. Northern blot analysis revealed that mRNA expression of the new caspase is predominant in skin. The invention thus relates to a new caspase homologue and its use to treat human and/or animal diseases, especially skin or skin related diseases.
2. State of the Art
Members of the caspase protein family are key mediators in the execution of apoptotic cell death. Specific inhibition of one or more caspases by CrmA, p35 or the peptide derivatives Ac-YVAD-CHO and Ac-DEVD-CHO revealed that several caspases are involved in apoptosis, mediated by stimulated Fas or 55-kDa tumor necrosis factor receptor (Los et al, 1995; Bertin et al, 1997; Nagata, 1997). Both receptors transduce the death signal through a cytoplasmic sequence motif called “death domain” (DD). After receptor trimerization this domain rapidly associates with a similar DD in the adapter molecules TRADD and/or FADD. The N-terminal end of FADD exhibits significant sequence homology to two similar regions within the prodomain of procaspase-8 and procaspase-10, referred to as death effector domains (DED), which allow heterodimerization of these caspases with FADD (Boldin et al, 1996; Muzio et al, 1996; Vincenz and Dixit, 1997). In the case of Fas, it has been demonstrated that receptor occupation results in FADD-mediated recruitment of procaspase-8 into the receptor complex. Receptor-associated procaspase-8 is then proteolytically cleaved to generate active caspase-8 (Yang et al, 1998). Once procaspase-8 becomes activated, it might initiate a proteolytic caspase activation cascade, since it is able to process, at least in vitro, all known caspases into their active subunits (Srinivasula et al, 1996). Activated caspases are believed to be the executors of cell death by aspartate-specific proteolysis of substrates, which results in the characteristic features of apoptosis, such as DNA degradation, nuclear condensation, membrane blebbing, etc. (Villa et al, 1997).
SUMMARY OF THE INVENTION
A first aspect of the current invention concerns proteins and functional fragments thereof forming new members of the caspase family. Another aspect of the invention relates to nucleic acids encoding the new members of the caspase family. The invention also pertains to the screening for compounds that inhibit the synthesis and/or biological activity of the new members of the caspase family. Another aspect of the present invention is the use of these proteins, nucleic acids and/or compounds in diagnosis and/or treatment of human and/or animal diseases, especially skin diseases and/or inappropriate wound healing. A further aspect of the invention is the use of the proteins, nucleic acids or compounds to modulate keratinization. In addition a pharmaceutical preparation to treat human and/or animal diseases, especially skin diseases, comprising proteins, nucleic acids or compounds belong to the scope of the invention.
AIMS AND DESCRIPTION OF THE INVENTION
The invention thus concerns a caspase-like polypeptide comprising SEQ. ID. NO. 2 or a polypeptide with at least 80% homology to the sequence or a functional fragment of the polypeptides. In addition, the invention relates to a human caspase-like polypeptide comprising SEQ. ID. NO. 4 or a polypeptide with at least 80% homology to the sequence or a functional fragment of the polypeptides.
The invention also pertains to an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide or a functional fragment thereof as mentioned above. Part of the invention is also an isolated nucleic acid molecule comprising SEQ. ID. NC). 1 or SEQ. ID. NO. 3 or a functional fragment thereof. The nucleic acid molecule of the present invention can be incorporated in a suitable vector or vector system while the vector preferably is an expression vector, in particular further comprising a regulatory element. The regulatory element directs in particular and preferably a tissue-specific expression. The scope of the current invention also belongs a genetically engineered host cell comprising the mentioned expression vector or vector present in a suitable expression system. The peptide and/or polypeptide of the invention may be used for the preparation of a medicament for the treatment of human or animal diseases such as skin diseases The peptide and/or polypeptide are extremely useful in the screening for compounds that modulate the biological activity of the peptide and/or polypeptide. Thus, the obtained compounds can be incorporated into a pharmaceutical preparation comprising in addition for instance the peptide and/or polypeptide and/or nucleic acid molecule according to the invention and suitable pharmaceutically acceptable excipients. In yet another aspect the invention features a transgenic animal harboring a nucleic acid molecule described above. In order to clarify various terms used in the current description the meaning thereof is further elaborated hereunder without being interpreted as a limitation of the scope of the invention.
REFERENCES:
patent: 6340740 (2002-01-01), Alnemri et al.
patent: 6376226 (2002-04-01), Alnemri
patent: 6432628 (2002-08-01), Alnemri et al.
patent: 2002/0081705 (2002-06-01), Mankovich
patent: 2002/0146804 (2002-10-01), Alnemri
patent: WO 91/03551 (1991-03-01), None
patent: WO 96/20276 (1996-04-01), None
patent: WO 96/13603 (1996-05-01), None
patent: WO 99/10504 (1999-03-01), None
patent: WO 00/04169 (2000-01-01), None
Poyet et al. Accession P31944. Jul. 1, 1993 (Alignment No. 1).*
Attwood et al. Which craft is best in bioinformatics? Comput. Chem. 2001, vol. 25(4), pp. 329-339.*
Ponting, C.P. Issues in predicting protein function from sequence. Brief. Bioinform. Mar. 2001, vol. 2(1), pp. 19-29.*
Abstract XP-002085023.
Abstract XP-002085024.
Abstract XP-002085055.
Abstract XP-002092996.
Fernandes-Alnemri et al., “CPP32, a Novel Human Apoptotic Protein with Homology toCaenorhabditis elegansCell Death Protein Ced-3 and Mammalian Interleukin-1 &bgr;-converting Enzyme”,The Journal of Biological Chemistry, vol. 269, No. 49, pp. 30761-30764, Dec. 9, 1994.
Hu et al., “Caspase-14 Is a Novel Developmentally Regulated Protease”,The Journal of Biological Chemistry, vol. 273, No. 45, pp. 29648-29653, Nov. 6, 1998.
Juan et al., “Identification and Mapping of Casp7, a Cysteine Protease Resembling CPP32&bgr;, Interleukin-1&bgr; Converting Enzyme, and CED-3”,Genomics, 40, pp. 86-93, 1997.
PCT International Preliminary Examination Report, PCT/EP99/04939, dated Sep. 19, 2000.
PCT International Search Report, PCT/EP99/04939, dated Aug. 24, 1999, 7 pages.
Van de Craen et al., “Identification of a new caspase homologue: caspase-14”,Cell Death and Differentiation, 5, pp. 838-846, 1998.
Cohen, Caspases: the executioners of apoptosis, Biochem J., 1997, pp. 1-16, vol. 326.
#Rendl et al., Caspase-14 Expression by Epidermal Keratinocytes is Regulated by Retinoids in a Differentiation-associated Manner, The Journal of Investigative Dermatology, 2002, pp. 1150-1155, vol. 119, No. 5.
#Haake et al., Apoptosis: A Role in Skin Aging? J. Investig. Dermatol. Symp. Proc., Aug. 1998, pp. 28-35, vol. 3, No. 1.
Declercq Wim
Fiers Walter
van de Craen Marc
Vandenabeele Peter
Achutamurthy Ponnathapu
Fronda Christian L.
Vlaams Interuniversitair Instituut Voor Biotechnologie VZW
LandOfFree
Caspase homologue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Caspase homologue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase homologue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3256187